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Abstract
Primary lymphedema is due to developmental and/or functional defects in the lymphatic system. It may affect any part of
the body, with predominance for the lower extremities. Twenty-seven genes have already been linked to primary lymph-
edema, either isolated, or as part of a syndrome. The proteins that they encode are involved in VEGFR3 receptor signaling.
They account for about one third of all primary lymphedema cases, underscoring the existence of additional genetic factors.
We used whole-exome sequencing to investigate the underlying cause in a non-consanguineous family with two children af-
fected by lymphedema, lymphangiectasia and distinct facial features. We discovered bi-allelic missense mutations in
ADAMTS3. Both were predicted to be highly damaging. These amino acid substitutions affect well-conserved residues in the
prodomain and in the peptidase domain of ADAMTS3. In vitro, the mutant proteins were abnormally processed and seques-
tered within cells, which abolished proteolytic activation of pro-VEGFC. VEGFC processing is also affected by CCBE1 muta-
tions that cause the Hennekam lymphangiectasia–lymphedema syndrome syndrome type1. Our data identifies ADAMTS3 as
a novel gene that can be mutated in individuals affected by the Hennekam syndrome. These patients have distinctive facial
features similar to those with mutations in CCBE1. Our results corroborate the recent in vitro and murine data that suggest a
close functional interaction between ADAMTS3 and CCBE1 in triggering VEGFR3 signaling, a cornerstone for the differentia-
tion and function of lymphatic endothelial cells.
Introduction
The lymphatic system is essential for tissue and body fluid
homeostasis. During development, lymphatic endothelial cells
differentiate from veins upon combined action of the PROX1
and SOX18 transcription factors. Several other proteins are
subsequently involved in the development of the lymphatic
system. Defective function of these proteins may result in pri-
mary (congenital) lymphedema. To date, mutations in twenty-
seven genes have been associated with either isolated or syn-
dromic primary lymphedema. These include CCBE1, FLT4,
FOXC2, GATA2, GJA1, GJC2, HGF, HRAS, IKBKG, ITGA9, KIF11,
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KRAS, PTPN11, PTPN14, RAF1, RASA1, SOS1, SOX18 and VEGFC
(reviewed by Brouillard et al (1)), as well as CELSR1 (2), EPHB4 (3),
FAT4 (4), PIEZO1 (5,6), RELN (7), RIT1 (8), (9), TSC1 and TSC2 (10).
These genes account for about one third of patients with pri-
mary lymphedema.
The central axis controlling lymphangiogenesis involves the
VEGFR3 receptor (encoded by FLT4) and its ligand, VEGFC. More
than 100 patients (families) have been reported with dominant,
recessive, or de novo inactivating mutations in VEGFR3 (1), and
two with a loss-of-function mutation in VEGFC (11,12). One re-
cessive homozygous mutation in PTPN14, a VEGFR3-specific
phosphatase, was discovered in a large consanguineous family
(13). Moreover, the extracellular protein CCBE1, which is in-
volved in the activation of VEGFC (14), is mutated in individuals
with the Hennekam syndrome (OMIM 235510) (15,16). Patients
with this recessive syndrome have generalized lymphatic
anomalies, a dysmorphic face and cognitive impairment. Mice
deficient in Ccbe1 die due to lymphatic abnormalities (17).
Recent biochemical data indicate that ADAMTS3 is a direct part-
ner of CCBE1 required for VEGFC activation (14).
Here, we report the identification of a novel gene mutated in
primary lymphedema. We discovered compound heterozygous
mutations in ADAMTS3 in two siblings with a phenotype remi-
niscent of the Hennekam lymphangiectasia–lymphedema syn-
drome. The unaffected parents were each a carrier for one of
the mutations. We show that each of the ADAMTS3 mutations
results in sequestration of the enzyme within the cell, and thus,
in the compound heterozygous state of the affected siblings, a
complete loss of ADAMTS3 function in regard to VEGFC activa-
tion. This underscores the crucial role of ADAMTS3 in the regu-
lation of VEGFR3 signaling pathway.
Results
A family with mutations in ADAMTS3
The parents in family LE-69 are of Western European origin and
non-consanguineous, with no familial history of primary lymph-
edema or other lymphatic problems. They were clinically exam-
ined and appeared healthy. The mother gave birth to two
children, a girl (LE-69-10) and a boy (LE-69-11), who both pre-
sented with polyhydramnios and congenital lymphedema of the
lower extremities (as well as hydroceles for the boy) (Fig. 1A).
The girl had a prolonged intensive care unit stay, primarily
related to her lymphedema and feeding problems. She also has
protein-losing enteropathy, which at one time required elemen-
tal formula feeding via a gastrostomy tube. Her lymphedema is
rather widespread, but worse in the left lower extremity.
Increasing severity occurs in a dependent course, but is present
in her face, abdomen, genitalia and legs. The facial lymph-
edema is minimal. Her physical features of note include: flat fa-
cies, hypertelorism (intercanthal distance 4.25 cm), synophrys,
pseudo-strabismus, upward-slanting palpebral fissures, and
anteverted peaked nostrils. She has an unusual stellate shaped
umbilicus. She has a normal chest and cardiovascular exam.
She has no hepatosplenomegaly. She has growth hormone defi-
ciency, which is responding well to therapy, and complex mi-
graines. Otherwise, she is a healthy adolescent.
Her brother has had a more benign course. He had less
edema at birth. He had a spontaneous pneumothorax and re-
quired a chest tube. He also had protein-losing enteropathy, but
to a lesser degree than his sister, and never required gastro-
stomy feeding. He has no hepatic involvement and no evidence
of growth hormone deficiency. He has facial features similar to
those of his sister, including hypertelorism (intercanthal dis-
tance 4 cm) and strabismus. He has minimal facial lymph-
edema. Lymphedema in the extremities is more pronounced on
the left side. Secondary changes of his feet are milder than
those of his sister.
A rather unusual finding noticed in the girl, and to a lesser
degree in her brother, is the nearly complete resolution of the
lymphedema during febrile illness. She may even do without
her compression garments during these episodes. This is not
due to dehydration, nor to use of non-steroidal anti-inflamma-
tory agents. Incidentally, the girl has a chromosome 14p dele-
tion inherited from the unaffected father; no karyotype was
performed for the boy.
In order to identify the genetic cause of primary lymphedema
in this family, we explored the whole-exome sequencing data
from the index patient (LE-69-10, Fig. 1A) using Highlander
(Helaers et al, under revision). We unraveled only one heterozy-
gous polymorphism in CCBE1 (rs200772179, present 61 times in
gnomAD (http://gnomad.broadinstitute.org)) and no change in
FAT4. However, we discovered two concomitant nucleotide
changes in ADAMTS3. The corresponding amino acid substitu-
tions were predicted to be damaging or deleterious by Polyphen
2, Mutation Taster, SIFT, LRT, and with medium or high impact
by Mutation Assessor. Variant c.503T>C (nucleotide 503 from the
ATG of ADAMTS3) results from an A-to-G substitution at position
73, 414, 196 on chromosome 4 (based on reference genome as-
sembly hg19), which predicts a leucine 168 to a proline substitu-
tion (p.Leu168Pro). This change was found in the affected siblings
(LE-69-10 and -11) and the unaffected father (Fig. 1A). The second
variant found in the girl (LE-69-10), was an A-to-G change at posi-
tion 73, 188, 804, corresponding to a c.872T>C (p.Ile291Thr) sub-
stitution. It was also detected in the brother and the unaffected
mother. Neither variant was present in the 60, 706 WES of ExAC,
the 250 trios of GoNL (Genome of the Netherlands), nor our
internal cohort of 645 sequenced samples. The c.503T>C
(p.Leu168Pro) is present once within the 245, 264 alleles in
gnomAD, whereas the c.872T>C (p.Ile291Thr) is not. Thus, the
changes are extremely rare, which corroborates the note that the
two children are compound heterozygotes for two recessive mu-
tations in ADAMTS3. No other homozygous or compound hetero-
zygous mutation in ADAMTS3 was found within 78 additional
primary lymphedema index patients sequenced.
ADAMTS3-L168 and I291 are conserved residues
The c.503T>C; p.Leu168Pro (L168P) and c.872T>C; p.Ile291Thr
(I291T) substitutions were predicted to be damaging by several
software programs. However, they were not localized in do-
mains known to be crucial for ADAMTS3 activity, such as the
furin cleavage site or the amino acids of the peptidase domain
involved in zinc binding and catalytic activity (Fig. 1B).
Therefore, we aligned the amino acid sequences of ADAMTS3
from different species (from human to fish and reptile), focusing
on the regions encompassing the mutations (Fig. 2A). The pro-
domain (ending at the furin cleavage site, Fig. 1B) is only moder-
ately conserved. However, the L168P mutation is in the center of
a fully conserved 9-amino acid stretch (N-C-D-G-L-A-G-M-I),
suggesting an important role in enzymatic function. The second
mutation is located in the first half of the metalloproteinase do-
main, between the furin and the zinc-binding catalytic site
(Fig. 1B). This domain is well conserved among different species,
and remarkably, the I291T mutation is located within one of the
most conserved stretches of the sequence (Fig. 2A, right panel).
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We also verified the nature of the amino acids at these posi-
tions in the 18 other human ADAMTS proteins (Fig. 2B). The
L168 residue is embedded in a specific signature (S-X-C-X-G-L-
X-G) in the prodomain of all ADAMTSs (except ADAMTS13,
which contains a truncated prodomain). Proline is never present
at this position. Alignment at the level of the second mutation
also revealed a conserved sequence and showed that either I or
L are the preferred amino acids (with M and A being present in
ADAMTS17 and ADAMTS4, respectively). T is never observed at
this position. Alignments were finally performed with se-
quences of human ADAM family members (a family distinct but
related to ADAMTS) (Fig. 2C). This revealed the same S-X-C-X-G-
L-X-G signature at the level of the L168P mutation and showed
that an aliphatic amino acid (I, V, L) is found at the I291T posi-
tion, as in the ADAMTSs. Altogether these data strongly favor a
damaging effect of the two mutations identified in our patients.
Mutant ADAMTS3 proteins are abnormally cleaved and
not secreted in the conditioned medium
The extent of the damaging effect of the identified mutations
could not be predicted. Therefore, we developed a model
allowing regulation of the level of production of the recombi-
nant proteins in order to create conditions suitable for the iden-
tification of small activity differences. Cell layers and culture
media obtained from control and induced cells were analyzed
by Western blotting. With an antibody targeting the C-terminal
end of ADAMTS3, a 166 kDa product, corresponding to the pro-
peptide, was identified in the cell layer of the wild-type (WT)
and the two mutants (Fig. 3A). No immunoreactive material was
detected in the conditioned medium.
A second antibody, raised against an ADAMTS3 fragment en-
compassing the prodomain, confirmed the presence of a
166 kDa product in the cell layer of all the clones (Fig. 3B, upper
band). In cells expressing WT-ADAMTS3, additional bands were
observed in the cell layer (at 139 and 36 kDa) and in the condi-
tioned culture medium (36 and 25 kDa) (see Supplementary
Material, Fig. S1 for details of the fragments), demonstrating se-
cretion and illustrating the complex process of maturation and
cleavage of WT-ADAMTS3. The active form of ADAMTS3, which
has lost its prodomain and should migrate at 100–110 kDa, can-
not be detected by this antibody. The distribution pattern for
the L168P mutant indicated that the mutant enzyme accumu-
lated in the cell layer as the 166 kDa full-length polypeptide,
while it was undetectable in the culture medium (Fig. 3B). For
Figure 1. ADAMTS3 mutations in a recessive lymphedema family. (A) Pedigree of family LE-69 with ADAMTS3 mutations and pictures of the faces, legs and feet of the
two affected children, at different ages. (B) Structure and domains of ADAMTS3 protein, showing the furin cleavage site (red arrowhead), the position of the HA-tag and
the mutations c.503T>C; p.Leu168Pro (L168P) and c.872T>C; p.Ile291Thr (I291T). TSP, thrombospondin domain.
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the I291T mutant, the 166 kDa pro-ADAMTS3 was also observed
in the cell layer, together with other products (of 125, 97 and
47 kDa) absent from cells expressing the WT enzyme. No signal
was detected in the culture medium.
The maturation process of ADAMTS3 involves the cleavage of
the prodomain by proprotein convertases, such as furin, as well as
the removal of most of the procollagen N-propeptidase C-terminal
domain by cleavage at a site that remains to be defined
Figure 2. Amino acid conservation around ADAMTS3-L168P and I291T mutations. Alignments of human ADAMTS3 protein sequence with (A) ADAMTS3 in other spe-
cies; (B) the 18 other human ADAMTSs; and (C) the 20 human ADAMs. UniProt identification codes are provided between parentheses after the names. Positions of the
last amino acid in aligned sequences are also reported. Conserved residues as compared to human ADAMTS3 are highlighted in dark grey. Middle and light grey boxes
illustrate substitutions by amino acids with similar or close physicochemical properties, respectively.
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(Supplementary Material, Fig. S1) (18). Since the commercially
available ADAMTS3 antibodies are specific for the N- or the C-ter-
minal, they did not allow visualization of the active central do-
main. To overcome this, we inserted an HA-epitope in the spacer
region of ADAMTS3 (Fig. 1B, Supplementary Material, Fig. S1), ac-
cording to a strategy successfully used previously for ADAMTS2
(18). The use of an anti-HA antibody confirmed the presence of the
166 and 139 kDa products, as well as products migrating at 100–
110 kDa in cells expressing WT-ADAMTS3 (Fig. 3C). In the condi-
tioned medium, a 106 kDa band was identified, corresponding to
the released active form of ADAMTS3. Moreover, very high molec-
ular weight products were observed, consisting of cleaved
ADAMTS3 in complex with alpha2-macroglobulin (Fig. 3C). The lat-
ter is an almost universal inhibitor of endoproteinases, including
matrix metalloproteinases and ADAMs. It presents a cleavable
‘bait’ that, once proteolytically cleaved, causes conformational
changes that entrap the proteinase. It becomes then covalently an-
chored by transacylation. Formation of a covalent complex with
alpha2-macroglobulin is therefore a sign of proteolytic activity of
ADAMTS3 (19). For both mutants, the patterns of proteolytic matu-
ration of ADAMTS3 were clearly altered, and no ADAMTS3 was de-
tected in the conditioned medium (Fig. 3C).
ADAMTS3 mutants are unable to cleave VEGFC
Absence of immunoreactive material in the conditioned medium
of cells expressing the mutant ADAMTS3 did not completely rule
out the possibility that an active ADAMTS3 fragment, which
would encompass the metalloproteinase domain but not the epi-
topes recognized by the antibodies, could be secreted and active.
Therefore, the functional consequences of the ADAMTS3
Figure 3. Impact of ADAMTS3 mutations on its activation and on VEGFC processing. HEK293 cells transfected with empty vector () and clones conditionally expressing
(A, B) WT, L168P or I291T-ADAMTS3 or (C) HA-tagged forms, were cultured in presence of doxycyclin. Cell layers and conditioned culture media were collected after
48 h and analyzed using antibodies specific for (A) the C-terminal domain of ADAMTS3, (B) the prodomain or (C) the HA epitope. Details of the different fragments gen-
erated are given in Supplementary Material, Figure S1. (A) C-terminus-specific antibody sc-21488 detected the 166 kDa ADAMTS3 propeptide in the cell layer. Two back-
ground bands (*) were also present in the negative control. (B) N-terminal prodomain-specific antibody AF5465 showed bands at 166, 139 and 36 kDa in the cell layer for
WT-ADAMTS3, and at 36 and 25 kDa in the conditioned medium. The processing was strongly altered for the mutants, most notably by absence of products detected in
the culture medium. (C) HA-tagged proteins confirmed the complex pattern of proteolytic maturation. The active 106 kDa product was predominantly secreted in the
conditioned culture medium, where it is mostly covalently associated with alpha2-macroglobulin. (D) VEGFC processing in control HEK293 cells () and clones express-
ing the different forms of ADAMTS3 were co-cultured with HEK293 cells expressing VEGFC at a 1:1 ratio. The antibody AF2179 strongly recognized pro-VEGFC but less
efficiently its active mature form. Almost complete conversion of the precursor was observed in presence of WT-ADAMTS3, but no significant cleavage could be de-
tected for the mutants.
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mutations on processing of pro-VEGFC were evaluated. HEK293
cells express endogenously CCBE1, which has been shown to in-
crease the maturation of pro-VEGFC by ADAMTS3. Control
HEK293 cells or HEK293 cells expressing the different forms of
ADAMTS3 (WT, L168 or I291) were mixed at a 1:1 ratio with
HEK293 cells expressing pro-VEGFC (Fig. 3D). A complete conver-
sion was observed in presence of WT-ADAMTS3, as illustrated by
the almost total disappearance of the 31 kDa band, which is
cleaved into a smaller product (less efficiently recognized by the
antibody). In contrast, absence of cleavage was observed for the
L168P and I291T-ADAMTS3 mutants.
ADAMTS3 mutants are sequestered within cells
To determine if the mutant ADAMTS3 enzymes accumulated in
cells or were secreted but remained associated with the cell
layer (Fig. 3B), we performed immunofluorescence studies on
non-permeabilized and permeabilized cells (Fig. 4). Cells ex-
pressing WT-ADAMTS3 were faintly labeled, with or without
permeabilization, with the N-terminal antibody (not shown)
and the C-terminal antibody (Fig. 4). Thus, taking into account
all our experiments, processing and secretion of WT-ADAMTS3
was efficient, with normal cleavage of the C-terminal propepti-
dase domain and release into the conditioned medium. Similar
amounts of ADAMTS3 were seen around non-permeabilized
cells for the mutant proteins, but a significant accumulation of
both L168P and I291T mutants was noted inside the cells after
permeabilization, demonstrating impaired secretion (Fig. 4).
Altogether, these data demonstrate altered maturation and ab-
sence of secretion of ADAMTS3 mutants, explaining the ab-
sence of processing of pro-VEGFC into active VEGFC (Fig. 3D).
Discussion
The Hennekam syndrome, characterized by lymphangiectasia,
lymphedema, and typical facial features and cognitive impair-
ment, was described in 1989 (20). In 2009, CCBE1 recessive
mutations were shown to cause this syndrome (HKLLS1; OMIM
235510) (15). CCBE1 is involved in processing of VEGFC, the main
VEGFR3 ligand involved in lymphangiogenesis. CCBE1 defi-
ciency in mice and zebrafish results in drastically impaired lym-
phatic vasculature (15,17,21). A second gene, FAT4, encoding a
protocadherin, has been reported to cause a Hennekam-like
syndrome (HKLLS2; OMIM 616006) by homozygous or combined
heterozygous mutations (4). The function of FAT4 in lymphatic
vasculature is unknown.
According to current in vitro and animal model data, CCBE1
requires ADAMTS3 for efficient processing and activation of
VEGFC (Fig. 5A). Pro-VEGFC binding to VEGFR3 is assisted by
the N-terminal domain of CCBE1, but CCBE1 itself does not
process VEGFC (14); rather, the cleavage is performed by
ADAMTS3.
The CCBE1 N-terminal domain also binds to the extracellular
matrix, thereby restricting the localization of VEGFC processing,
whereas the C-terminal domain of CCBE1, containing two colla-
gen repeats, is required for VEGFC activation (22). Indeed, lack of
the C-terminal domain mimics the Ccbe1 knockout (22). The
ADAMTS3-CCBE1 complex can also form independently of
VEGFR3 and cleave VEGFC, but proper localization is required
for adequate lymphangiogenesis (23). ADAMTS3 seems a requi-
site for this. Indeed, we reported elsewhere that an ADAMTS3
change (c.1694G>A; p.Arg595Gln), which does not change
VEGFC processing but reduces ADAMTS3 interaction with
CCBE1, renders ADAMTS3 unable to retain CCBE1 at the cell sur-
face, resulting in disruption of VEGFR3 signaling (24).
Here, we identified two compound heterozygous recessive
mutations in ADAMTS3 in two siblings with primary lymph-
edema, lymphangiectasia and distinct facial features. The
symptoms are reminiscent of those of Hennekam syndrome 1,
caused by CCBE1 mutations (OMIM 235510), underscoring the
likely cooperative function of the two proteins in the same cel-
lular process. We propose to name this clinical entity caused by
ADAMTS3 mutations Hennekam lymphangiectasia–lymph-
edema syndrome 3 (HKLLS3), given that HKLLS2 (OMIM 616006)
is caused by FAT4 mutations (4).
Figure 4. Effects of ADAMTS3 mutations on its secretion. Visualization of ADAMTS3 on non-permeabilized (left) and permeabilized (right) cells stained with SC-21486
antibody and a secondary antibody coupled to Alexa Fluor 546 (red). Nuclei were stained with DAPI (blue). Control cultures (Ctrl-) consisted of HEK293 cells containing
the expression vector for WT-ADAMTS3 but in the absence of doxycycline, to prevent ADAMTS3 expression. WT, L168P and I291T refer to HEK293 clones cultured for
48 h in presence of doxycycline to induce expression of WT-ADAMTS3, or L168P or I291T-ADAMTS3 mutants, respectively. Scale bars ¼ 10 mm.
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The two identified mutations (c.503T>C; p.Leu168Pro and
c.872T>C; p.Ile291Thr) result in loss of function of ADAMTS3
and defective VEGFC activation (Fig. 5B). Each of the mutations
was present in one of the parents, who were unaffected. Thus,
haploinsufficiency of ADAMTS3 is not pathogenic; 50% of en-
zyme is sufficient to cleave and activate enough VEGFC. This is
in agreement with our previous observations that heterozygous
Adamts3þ/ mice were healthy and reproduced well (25).
Our in vitro experiments demonstrated that the two mutants
of ADAMTS3 displayed an abnormal electrophoretic profile
(Fig. 3). Similar to ADAMTS2 (18), the activity of ADAMTS3 is
largely regulated by several proteolytic processes
(Supplementary Material, Fig. S1). Two main cleavages are re-
quired to confer full activity. First, the prodomain must be ex-
cised by proprotein convertases, such as furin, at a specific basic
site (MRRRRH in ADAMTS3), between the prodomain and the
peptidase domain. The second crucial cleavage occurs at the be-
ginning of the C-terminal procollagen N-propeptidase (PNP) do-
main, at a site not yet precisely identified. This cleavage might
be performed through an autocatalytic process. Persistence of
the PNP domain in the homologous ADAMTS2 strongly reduced
its activity and leads to formation of aggregates at the cell sur-
face and in the extracellular matrix (Colige et al., unpublished).
Although the exact mechanism of inhibition is unknown, the
PNP domain could reduce interactions with the substrates (18).
The discovery of reduced mutant ADAMTS3 activity could re-
flect very low bio-availability of the enzyme. In our experiments,
the maturation process of the WT-ADAMTS3 occurred as ex-
pected. In contrast, the two mutations have dramatic conse-
quences on ADAMTS3 secretion and maturation. None of the
mutants was detected in the conditioned medium (Fig. 3),
whereas strong intracellular accumulation was evident by immu-
nofluorescence (Fig. 4). The L168P mutant accumulates in the cell
layer in its full-size, possibly because its cleavage by proprotein
convertases is hampered. For the I291T mutant, products of ab-
normal sizes were also observed (Fig. 3B), clearly illustrating mat-
uration defects. Altogether, absence of secretion and abnormal
processing explain why the mutants of ADAMTS3 were unable to
cleave and activate pro-VEGFC in the extracellular compartment.
Amelioration of the lymphedema with fever in our patients
is an intriguing clinical observation. It raises the hypothesis
that the mutations are temperature sensitive and that elevated
temperatures may result in improved protein secretion. To ad-
dress this question, we cultured WT and mutants ADAMTS3
proteins at different temperatures (37, 39 and 41 C), in presence
of VEGFC (Supplementary Material, Fig. S2). However, no secre-
tion of the mutants was seen in any condition, and even the se-
cretion and activation of the WT ADAMTS3 was impaired at
41 C. Thus, this clinical observation remains unexplained.
The bi-allelic loss of function of ADAMTS3 reported here is
not lethal in human beings. In contrast, the Adamts3/ mice
died around E15.0 with severe edema due to complete lack of
lymphatic vessels (25). Several hypotheses can be made to ex-
plain these differential effects. Species-specific compensation
by other enzymes during embryonic development could occur,
although ADAMTS2 and ADAMTS14 (the two closest homologs
of ADAMTS3) are unable to cleave pro-VEGFC in vitro (Colige
et al., unpublished). Activation and secretion of the mutant
ADAMTS3 might also be less affected in vivo during embryogen-
esis than in HEK293 cells, providing sufficient residual activity
for embryonic survival, but insufficient activity for normal de-
velopment and/or homeostasis of the lymphatic network.
In addition to endothelial cells, ADAMTS3 is significantly ex-
pressed in other tissues, such as in cartilage where it is
considered to be the enzyme responsible for cleavage of the
aminopropeptide of type II procollagen. Since our patients do
not have developmental delay or major skeletal defects, it prob-
ably indicates that lack of ADAMTS3 secretion is compensated,
at least partially, by another collagen aminopeptidase, likely
ADAMTS2 (25). However, involvement of ADAMTS3 in type II
procollagen maturation could explain the characteristic facial
features of the subjects. It also suggests that periodic evaluation
of cartilage and joint integrity of the patients may be indicated.
ADAMTS3 is also strongly expressed in the brain, but no obvious
neurological disorder was identified in the patients. Finally, the
Adamts3 -/- mice present with reduced liver development (25).
No obvious signs of hepatic dysfunction were evidenced in our
patients, albeit no extensive liver evaluation was performed.
In conclusion, our discovery of ADAMTS3 mutations in hu-
man subjects with lymphangiectasia, lymphedema and distinct
facial features (Hennekam lymphangiectasia–lymphedema syn-
drome 3) reveals another key component in the development of
primary lymphedema. Therefore, individuals with phenotypic
signs reminiscent of the Hennekam syndrome need to be
screened not only for CCBE1 and FAT4 mutations, but also for al-
terations in ADAMTS3. These data give unequivocal evidence
for the important physiological role that ADAMTS3 plays in
VEGFC activation in man.
Figure 5. Mechanism of VEGFC/VEGFR3 activation is altered by ADAMTS3 mutations. (A) Pro-ADAMTS3 is activated and secreted in the extracellular space where it
cleaves pro-VEGFC into active VEGFC, in conjunction with CCBE1. Binding of activated VEGFC to VEGFR3 induces phosphorylation of the receptor, which triggers down-
stream signaling. (B) Mutants of ADAMTS3 (c.503T>C; p.Leu168Pro and c.872T>C; p.Ile291Thr) are sequestered in the cell and cannot induce VEGFC cleavage and
activation.
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Materials and Methods
Patients and sequencing
DNA samples and phenotypic data from family LE-69 (Fig. 1A)
were collected (G.T. and J.P.). Informed consent was obtained
from the patients prior to their participation in the study, as ap-
proved by the Ethical Committee of the Medical Faculty at
University of Louvain (Brussels, Belgium) and the Committee for
the Protection of Human Subjects of Vanderbilt University
(Nashville, TN, USA). DNA was extracted using the Wizard
Genomic kit (Promega) and concentration measured on a
Nanodrop 8000 (Thermo Scientific). Exome sequencing of the in-
dex case (LE-69.10) was performed on a SOLiD 5500xl with a
Wildfire module (Life Technologies), after exon capture with
SureSelect v5 kit (Agilent). The reads were aligned with
Lifescope (Life Technologies) and bam files were imported into
Highlander for analysis (http://sites.uclouvain.be/highlander/),
a software developed in our laboratory (Helaers et al, under revi-
sion). Variants were called with the Genome Analysis Toolkit
(GATK, Broad Institute) and annotated with a number of soft-
ware programs, including dbNSFP v2 (26).
Filtering in Highlander was performed using following crite-
ria: variants within a list of 600 candidate genes; not detected
in >3 distinct pathologies including lymphedema; read depth of
at least 10 at this position; absent or present at <0, 15% (corre-
sponding to the estimated prevalence of primary lymphedema
in the population) in the Exome Aggregation Consortium data-
base (ExAC, http://exac.broadinstitute.org); predicted damaging
by at least four prediction software programs; and visually eval-
uated in the Integrative Genomics Viewer (IGV, http://software.
broadinstitute.org/software/igv/). The underlying hypothesis
was recessive inheritance, and thus only genes with a homozy-
gous mutation or two independent mutations were kept.
We used PCR and Sanger sequencing with genomic primers
50-CTTTAACATCACGGCATTTGG-30 and 50-TCGTCTTCGCATTA
TTCCAAG-30 to study co-segregation of the mutation c.503T>C;
p.Leu168Pro (L168P), and 50-TGACTACCTTTCAGAGTTCAG-30
and 50-TGGAAGTCTCCACTCATGTG-30 for mutation c.872 T>C;
p.Ile291Thr (I291T) in the family.
Expression vectors
The pcDNA4/TO vector containing the human ADAMTS3 coding
sequence (26) was used for site-directed mutagenesis.
Oligonucleotides were designed using QuikChange Primer Design
(Agilent). For c.503T>C (p.Leu168Pro), we used primers 50-TCAGCA
ACTGTGATGGTCCGGCTGGAATGATAAAAAG-30 and 50-CTTTTTAT
CATTCCAGCCGGACCATCACAGTTGCTGA-30. For c.872T>C (p.Ile2
91Thr), we used 50-CCTGACCCTAATGAACATTGTGAATGAAACTT
ACCATGATGAGTCC-30 and 50-GGACTCATCATGGTAAGTTTCAT
TCACAATGTTCATTAGGGTCAGG-30. In brief, 10 ng of plasmid DNA
was used as template for PCR amplification with Pfu Turbo DNA po-
lymerase. The amplification products were verified on 1% agarose
gels, DpnI digested to remove template DNA, and transformed in
JM109 bacteria for amplification. The entire coding sequence was
verified using Sanger sequencing.
To create different hemagglutinin (HA)-flagged ADAMTS3
proteins, the wild-type vector was linearized with XhoI (New
England Biolabs) and used as a template for PCR-amplification
with Phusion High Fidelity DNA polymerase (New England
Biolabs). Primer A (50-CACCACGGGTACCTTTACCCATACGATGT
TCCAGATTACGCTAAGATGTTTGATATACCCCCTGGGGCT-30)
contained the only endogenous KpnI site in ADAMTS3 (bold),
followed by a sequence of 27 nt encoding the HA epitope (under-
lined) inserted between nucleotides c.2187_2188. Primer B (50-
TTGTTCGGGCCCAAGCTTGGTAC-30) was downstream of the
KpnI site in the multiple cloning site of the vector. The HA-
coding sequence was therefore inserted at the beginning of the
spacer domain (Fig. 1B). This KpnI cassette was subsequently
replaced in the wild-type (WT) and mutant expression vectors.
For VEGFC expression, the full-length human coding sequence
(22) was inserted between the BamHI and XbaI sites of pcDNA4/
TO (TetOn System; Invitrogen). Plasmids were purified with the
Plasmid Maxi kit (Qiagen) and sequence-verified.
Stable cell lines
Human embryonic kidney HEK293 cells expressing a
tetracyclin-sensitive repressor (27) were transfected with wild-
type or mutant ADAMTS3 or VEGFC expression vectors, using
GeneJuice Transfection Reagent (Novagen). After selection
(Zeocin, 300 mg/ml; Thermo Fisher Scientific), subcloning was
performed to identify clones producing the recombinant pro-
teins only when induced with 1 mg/ml doxycycline (Sigma-
Aldrich). Selected clones were subsequently cultured in DMEM
supplemented with Zeocin (300mg/ml), blasticidin (4 mg/ml) and
10% fetal bovine serum.
ADAMTS3 profiling
Transfected HEK293 cells conditionally expressing wild-type or
mutant ADAMTS3 (HA-tagged or not) were cultured until con-
fluent. The culture medium was then replaced by fresh medium
containing doxycycline (1mg/ml) to induce ADAMTS3 expres-
sion. After 48 h, the conditioned media were collected and the
cell layers were scraped in Laemmli denaturation buffer (with
100 mM DTT). Samples were separated by electrophoresis (7.5 or
12.5% SDS-PAGE) and transferred to PVDF membrane (NEN Life
Sciences Products). Membranes were blocked (60 min, 3% BSA in
PBS-Tween) and incubated with the anti-ADAMTS3 antibody
(sc-21486, Santa Cruz, recognizing the C-terminal part, or
AF5465, R&D Systems, raised against the N-terminal part) or
with the anti-HA antibody (11867423001, Roche) for 18 h at 4 C.
The secondary peroxidase-conjugated antibodies (1 h at RT; 1/
2000) were from Dako. Peroxidase activity was revealed with an
enhanced chemiluminescence assay (ECLTM Prime Western
Blotting System, Sigma Aldrich) in an ImageQuantTM LAS 4000
(GE Healthcare).
VEGFC processing
HEK293 cells transfected to conditionally express ADAMTS3 or
VEGFC were co-cultured at a 1:1 ratio. At confluence, doxycy-
cline was added for 48 h. The conditioned media were collected
and the cell layers were scraped in Laemmli denaturation buffer
(with 100 mM DTT). Samples were resolved on 12.5% SDS-PAGE)
and transferred to PVDF. Membranes were blocked (60 min in
3% BSA in PBS-Tween) and incubated 18 h at 4 C with the anti-
VEGFC antibody (AF2179, R&D Systems), followed by an anti-
sheep peroxidase-conjugated secondary antibody (1/2000,
Dako). Peroxidase activity was revealed as described above.
ADAMTS3 cytochemistry
HEK293 cells conditionally expressing wild-type or mutant
ADAMTS3 were cultured until 50% confluent, then treated with
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doxycycline for 48 h. After fixation (4% formaldehyde in PBS for
10 min), cells were either left untreated, or permeabilized (3 min
in PBS containing 0.1% Triton X-100). ADAMTS3 staining was
performed using two different antibodies (sc-21486 from Santa
Cruz and AF5465 from R&D Systems, at a 1/50 dilution) for 2 h at
37 C, followed by Alexa Fluor-546 donkey anti-goat IgG (A11056,
Life Technologies) or Fluor-488 rabbit anti-sheep IgG (ab150181,
Abcam) for 1 h. Nuclei were counter-stained with DAPI (1/1000,
Life Technologies, D1306) in PBS. After mounting in Dako fluo-
rescent mounting medium (s3023, Dako), cells were observed
with an Eclipse TiS microscope (Nikon).
Genbank accession number for ADAMTS3 mRNA: NM_014243.
The variants were submitted to LOVD (adamts3.lovd.nl).
Supplementary Material
Supplementary Material is available at HMG online.
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